|
|
 Previous Article | Table of Contents | Next Article 
The pattern of mutational involvement of RAS genes in human hematologic
malignancies determined by DNA amplification and direct sequencing
HG Ahuja, A Foti, M Bar-Eli and MJ Cline
Department of Medicine, Jonsson Cancer Center, UCLA School of Medicine
90024-1678.
DNA from 161 patients with various forms of hematologic malignancies were
investigated for mutations in exons 1 and 2 of the N-RAS, K-RAS and Ha-RAS
gene by direct sequencing of DNA amplified in vitro by the polymerase chain
reaction. Mutations involving either codons 11, 12, or 13 of the N-RAS gene
were identified in 18 of the 161 patients. The relative frequencies of
N-RAS gene mutations in these hematologic disorders was as follows: acute
myelogenous leukemia (AML), 15%; acute lymphoblastic leukemia (ALL), 14%;
myelodysplastic syndromes, 24%; and myeloid and lymphoid blast crisis of
chronic myelogenous leukemia (CML), 3%. No correlation was observed between
the presence of mutations and cytologic features or immunophenotype of
these malignancies. Mutations involving codons 12 or 13 were equally
prevalent, with a glycine to aspartic acid substitution being the most
frequently encountered change. A single T-ALL case had a codon 11 mutation
resulting in substitution of alanine with threonine. We failed to find
mutations in exons 1 and 2 of the K-RAS or Ha-RAS genes in any case except
a single AML with a mutation in codon 61 of the K-RAS gene. Also, no
mutations were identified in chronic phase of CML, chronic lymphocytic
leukemia. Ph1 positive ALL, non-Hodgkin's lymphoma, Hodgkin's disease, or
multiple myeloma. These results indicate that RAS mutations, especially
those involving exon 1 of the N-RAS gene, are frequent only in a subset of
hematologic malignancies.
Volume 75,
Issue 8,
pp. 1684-1690,
04/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. T. Bowen, M. E. Frew, R. Hills, R. E. Gale, K. Wheatley, M. J. Groves, S. E. Langabeer, P. D. Kottaridis, A. V. Moorman, A. K. Burnett, et al.
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years
Blood,
September 15, 2005;
106(6):
2113 - 2119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Grant
Reducing cholesterol and overcoming drug resistance
Blood,
September 15, 2004;
104(6):
1598 - 1599.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tartaglia, S. Martinelli, G. Cazzaniga, V. Cordeddu, I. Iavarone, M. Spinelli, C. Palmi, C. Carta, A. Pession, M. Arico, et al.
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia
Blood,
July 15, 2004;
104(2):
307 - 313.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Clark, L. Zhong, D. Filiault, S. Perman, Z. Ren, M. Gould, and X. Yang
Anti-Leukemia Effect of Perillyl Alcohol in Bcr/Abl-Transformed Cells Indirectly Inhibits Signaling through Mek in a Ras- and Raf-Independent Fashion
Clin. Cancer Res.,
October 1, 2003;
9(12):
4494 - 4504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Mortazavi, J. A. Tooze, E. C. Gordon-Smith, and T. R. Rutherford
N-RAS gene mutation in patients with aplastic anemia and aplastic anemia/ paroxysmal nocturnal hemoglobinuria during evolution to clonal disease
Blood,
January 15, 2000;
95(2):
646 - 650.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Voice, R. L. Klemke, A. Le, and J. H. Jackson
Four Human Ras Homologs Differ in Their Abilities to Activate Raf-1, Induce Transformation, and Stimulate Cell Motility
J. Biol. Chem.,
June 11, 1999;
274(24):
17164 - 17170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Beaupre, M. Talpaz, F. C. Marini III, R. J. Cristiano, J. A. Roth, Z. Estrov, M. Albitar, M. H. Freedman, and R. Kurzrock
Autocrine Interleukin-1{beta} Production in Leukemia: Evidence for the Involvement of Mutated RAS6
Cancer Res.,
June 1, 1999;
59(12):
2971 - 2980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Beaupre and R. Kurzrock
RAS and Leukemia: From Basic Mechanisms to Gene-Directed Therapy
J. Clin. Oncol.,
March 1, 1999;
17(3):
1071 - 1071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Cline
The Molecular Basis of Leukemia
N. Engl. J. Med.,
February 3, 1994;
330(5):
328 - 336.
[Full Text]
|
|
|
|
|
